JP2006503845A5 - - Google Patents

Download PDF

Info

Publication number
JP2006503845A5
JP2006503845A5 JP2004539056A JP2004539056A JP2006503845A5 JP 2006503845 A5 JP2006503845 A5 JP 2006503845A5 JP 2004539056 A JP2004539056 A JP 2004539056A JP 2004539056 A JP2004539056 A JP 2004539056A JP 2006503845 A5 JP2006503845 A5 JP 2006503845A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
hydrogen
halo
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004539056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503845A (ja
Filing date
Publication date
Priority claimed from GBGB0222493.9A external-priority patent/GB0222493D0/en
Application filed filed Critical
Publication of JP2006503845A publication Critical patent/JP2006503845A/ja
Publication of JP2006503845A5 publication Critical patent/JP2006503845A5/ja
Withdrawn legal-status Critical Current

Links

JP2004539056A 2002-09-27 2003-09-25 Cb2受容体モジュレーターとしてのピリジン誘導体 Withdrawn JP2006503845A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds
PCT/EP2003/010930 WO2004029026A1 (en) 2002-09-27 2003-09-25 Pyridine derivatives as cb2 receptor modulators

Publications (2)

Publication Number Publication Date
JP2006503845A JP2006503845A (ja) 2006-02-02
JP2006503845A5 true JP2006503845A5 (https=) 2006-05-18

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004539056A Withdrawn JP2006503845A (ja) 2002-09-27 2003-09-25 Cb2受容体モジュレーターとしてのピリジン誘導体

Country Status (23)

Country Link
US (1) US20060240048A1 (https=)
EP (1) EP1565442B1 (https=)
JP (1) JP2006503845A (https=)
KR (1) KR20050071514A (https=)
CN (1) CN1703402A (https=)
AR (1) AR041395A1 (https=)
AT (1) ATE378317T1 (https=)
AU (1) AU2003268907A1 (https=)
BR (1) BR0314635A (https=)
CA (1) CA2500231A1 (https=)
DE (1) DE60317555T2 (https=)
ES (1) ES2294313T3 (https=)
GB (1) GB0222493D0 (https=)
IS (1) IS7809A (https=)
MA (1) MA27448A1 (https=)
MX (1) MXPA05003263A (https=)
NO (1) NO20052028L (https=)
NZ (1) NZ538943A (https=)
PL (1) PL375990A1 (https=)
RU (1) RU2005112752A (https=)
TW (1) TW200413321A (https=)
WO (1) WO2004029026A1 (https=)
ZA (1) ZA200502084B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TW200505902A (en) * 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
CA2569887A1 (en) 2004-06-09 2005-12-22 Glaxo Group Limited Pyrrolopyridine derivatives
PE20070239A1 (es) * 2005-08-09 2007-04-01 Glaxo Group Ltd Derivados de imidazopiridina con actividad sobre los receptores cannabinoides
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
JP2009536613A (ja) * 2006-04-07 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb2受容体を調節する化合物
WO2008040649A2 (en) 2006-10-04 2008-04-10 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
EA016521B1 (ru) * 2007-02-22 2012-05-30 Хемерус Медикал, Ллк Аппарат высокой производительности для фильтрации биологических жидкостей
MX2011007663A (es) * 2009-01-22 2011-08-15 Raqualia Pharma Inc Compuestos de sulfona heterociclica, saturada y sustituida en n, con actividad agonistica del receptor de cb2.
KR20120002581A (ko) 2009-03-30 2012-01-06 아스텔라스세이야쿠 가부시키가이샤 피리미딘 화합물
CN102711764A (zh) * 2009-08-24 2012-10-03 纽若斯丹公司 神经刺激性哌嗪的合成
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (en) * 2016-09-22 2018-03-29 Srf Limited Process for the preparation of haloalkyl derivatives of nicotinic acid
PE20210368A1 (es) 2018-06-27 2021-02-26 Eth Zuerich Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2
JP7456948B2 (ja) 2018-06-27 2024-03-27 エフ. ホフマン-ラ ロシュ アーゲー 放射性標識カンナビノイド受容体2リガンド
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
EP3666759A1 (en) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Similar Documents

Publication Publication Date Title
JP2006503845A5 (https=)
RU2435757C2 (ru) Производные 3-циклил-2-(4-сульфамоилфенил)-n-циклилпропионамида, применимые для лечения нарушенной переносимости глюкозы и диабета
RU2005112752A (ru) Производные пиридина в качестве модуляторов рецептора сb2
JP2007538024A5 (https=)
AU688739B2 (en) Method and composition for the treatment of Parkinson's disease
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
JP2013531031A5 (https=)
JP2014037426A5 (https=)
US9381177B2 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
RU2001132632A (ru) Производные пиперазина, применимые в качестве антагонистов CCR5
JP2007145875A5 (https=)
JP2004506736A5 (https=)
KR970704435A (ko) 헤테로시클릭 화합물의 도파민-D 리간드로서의 용도(Use of Heterocyclic Compounds as Dopamines-D Ligands)
JP2003012668A5 (https=)
JP2015504067A5 (https=)
JP2007519649A5 (https=)
JP2004529926A5 (https=)
JP2013510825A5 (https=)
KR960014125A (ko) 헤테로사이클 화합물, 이들의 제조방법 및 용도
JP2020532547A5 (https=)
JP2011521911A5 (https=)
JP2008539267A5 (https=)
JP2015524450A5 (https=)
JP2013520473A5 (https=)
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов